Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications

  • David J Bjorkman
    Requests for reprints should be addressed to David J. Bjorkman, MD, Division of Gastroenterology, Room 4R118 SOM, University of Utah School of Medicine, 50 North Medical Drive, Salt Lake City, Utah 84132
    Division of Gastroenterology, University of Utah School of Medicine, Salt Lake City, Utah, USA
    Search for articles by this author


      Gastrointestinal (GI) toxicity is a major limiting factor in the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Because of the widespread use of these medications, the morbidity and costs associated with GI complications of NSAID use are significant. On the other hand, the costs of providing prophylactic cotherapy to all patients to prevent NSAID-induced ulcers and bleeding are prohibitive. The presence of specific risk factors (advanced age, prior peptic ulcer disease and bleeding, high NSAID doses and concomitant therapy with corticosteroids or anticoagulants) identifies patients who are most likely to have a GI complication. The recognition of these risks in specific patients may influence therapeutic decisions that could decrease the morbidity and costs of NSAID therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Langman M.J.S.
        Ulcer complications and nonsteroidal anti-inflammatory drugs.
        Am J Med. 1988; 84: 15-19
        • Edelson J.T.
        • Tosteson A.N.A.
        • Sax P.
        Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal bleeding.
        JAMA. 1990; 264: 41-47
        • Graham D.Y.
        • Agrawal N.M.
        • Roth S.H.
        Prevention of NSAID-induced gastric ulcer with misoprostol.
        Lancet. 1988; ii: 1277-1280
        • Armstrong C.P.
        • Blower A.L.
        Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration.
        Gut. 1987; 28: 527-532
        • Hawkey C.J.
        Non-steroidal anti-inflammatory drugs and ulcers.
        BMJ. 1990; 300: 278-284
        • Silverstein F.E.
        • Graham D.Y.
        • Senior J.R.
        • et al.
        Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs.
        Ann Intern Med. 1995; 123: 241-249
        • Langman M.J.S.
        • Weil J.
        • Wainwright P.
        • et al.
        Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.
        Lancet. 1994; 343: 1075-1078
        • Bloom B.S.
        Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis.
        Am J Med. 1988; 84: 20-24
        • Holzer S.S.
        • Cuerdon T.
        Development of an economic model comparing acetaminophen to NSAIDs in the treatment of mild-to-moderate osteoarthritis.
        Am J Managed Care. 1996; 2: S15-S26
        • Larkai E.N.
        • Smith J.L.
        • Lidsky M.D.
        • Graham D.Y.
        Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.
        Am J Gastroenterol. 1987; 82: 1153-1158
        • Lockard Jr, O.O.
        • Evey K.J.
        • Butt J.H.
        • Silvoso G.R.
        • Sisk C.
        • Holt S.
        The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy.
        Gastrointest Endosc. 1980; 26: 5-7
        • Silvoso G.R.
        • Ivey K.J.
        • Butt J.H.
        • et al.
        Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy.
        Ann Intern Med. 1979; 91: 517-520
        • Jaszewski R.
        Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy.
        J Clin Gastroenterol. 1990; 12: 10-13
        • Graham D.Y.
        • White R.H.
        • Moreland L.W.
        • et al.
        Duodenal and gastric ulcer prevention with misoprostol in arthritic patients taking NSAIDs.
        Ann Intern Med. 1993; 119: 257-262
        • Somerville K.
        • Faulkner G.
        • Langman M.
        Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.
        Lancet. 1986; 1: 462-464
        • Walt R.
        • Katschinski B.
        • Logan R.
        • Ashley J.
        • Langman M.
        Rising frequency of ulcer perforation in elderly people in the United Kingdom.
        Lancet. 1986; i: 489-492
        • Gabriel S.E.
        • Jaakkimainen L.
        • Bombardier C.
        Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs.
        Ann Intern Med. 1991; 115: 787-796
        • Carson J.L.
        • Strom B.L.
        • Soper K.A.
        • West S.L.
        • Morse M.L.
        The association of nonsteroidal anti-inflammatory drugs with upper gastro-intestinal tract bleeding.
        Arch Intern Med. 1987; 147: 85-88
        • Hawkey C.J.
        Future treatments for arthritis.
        Gastroenterology. 1995; 109: 614-616
        • Fries J.F.
        NSAID gastropathy.
        J Musculoskel Med. 1991; 8: 21-28
        • Tamblyn R.
        • Berkson L.
        • Dauphinee W.D.
        • et al.
        Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice.
        Ann Intern Med. 1997; 127: 429-438
        • Bjorkman D.J.
        • Kimmey M.B.
        Nonsteroidal anti-inflammatory drugs and gastrointestinal disease.
        Dig Dis. 1995; 13: 119-129
        • Taha A.S.
        • Hudson N.
        • Hawkey C.J.
        • et al.
        Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1996; 334: 1435-1439
        • Hawkey C.J.
        • Karrasch J.A.
        • Szcepanski L.
        • et al.
        Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1998; 338: 727-734
        • Yeomans N.D.
        • Tulassay Z.
        • Juhasz L.
        • et al.
        A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1998; 338: 719-726
        • Agrawal N.M.
        • Roth S.
        • Graham D.Y.
        • et al.
        Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer.
        Ann Intern Med. 1991; 115: 195-200
        • Lanza F.L.
        • Kochman R.L.
        • Geis G.S.
        • Rack E.M.
        • Deysach L.G.
        A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits.
        Am J Gastroenterol. 1991; 86: 1743-1748
        • Raskin J.B.
        • White R.H.
        • Jackson J.E.
        • et al.
        Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers.
        Ann Intern Med. 1995; 123: 344-350
        • Elliott S.L.
        • Yeomans N.D.
        • Buchanan R.R.C.
        • et al.
        Long-term effects of misoprostol on gastropathy induced by nonsteroidal anti-inflammatory drugs (NSAID).
        Gastroenterology. 1990; 98 (Abstr.): A40
        • Levine J.S.
        Misoprostol and nonsteroidal anti-inflammatory drugs.
        Ann Intern Med. 1995; 123: 309-310
        • Maetzel A.
        • Ferraz M.B.
        • Bombardier C.
        The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
        Arthritis Rheum. 1998; 41: 16-25
        • Garcia-Rodriguez L.A.
        • Jick H.
        Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.
        Lancet. 1994; 343: 769-772
        • Griffin M.R.
        • Piper J.M.
        • Daugherty J.R.
        • Snowden M.
        • Ray W.A.
        Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.
        Ann Intern Med. 1991; 114: 257-263
        • Hallas J.
        • Lauritsen J.
        • Dalsgard Villadsen H.
        • Freng Gram L.
        Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high risk groups by excess risk estimates.
        Scand J Gastroenterol. 1995; 30: 438-444
        • Singh G.
        • Rosen-Ramey D.
        NSAID induced gastrointestinal complications.
        J Rheumatol Suppl. 1998; 51: 8-16
        • Schubert T.T.
        • Bologna S.D.
        • Nensey Y.
        • Schubert A.B.
        • Mascha E.J.
        • Ma C.K.
        Ulcer risk factors.
        Am J Med. 1993; : 413-418
        • Henry D.
        • Dobson A.
        • Turner C.
        Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs.
        Gastroenterology. 1993; 105: 1078-1088
        • Stalnikowicz-Darvasi R.
        Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events.
        J Clin Gastroenterol. 1995; 21: 13-16
        • Roderick P.J.
        • Wilkes H.C.
        • Meade T.W.
        The gastrointestinal toxicity of aspirin.
        Br J Clin Pharmacol. 1993; 35: 219-226
        • Piper J.M.
        • Ray W.A.
        • Daugherty J.R.
        • Griffin M.R.
        Corticosteroid use and peptic ulcer disease.
        Ann Intern Med. 1991; 114: 735-740
        • Shorr R.I.
        • Ray W.A.
        • Daugherty J.R.
        • Griffin M.R.
        Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulant places elderly persons at high risk for hemorrhagic peptic ulcer disease.
        Arch Intern Med. 1993; 153: 1665-1670
        • Rockall T.A.
        • Logan R.F.
        • Devlin H.B.
        • Northfield T.C.
        Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom.
        BMJ. 1995; 311: 222-226
      1. Kurata JH, Nogawa AN, Noritake D. NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia. J Fam Pract 1997;45:227–223.

        • Kelly J.P.
        • Kaufman D.W.
        • Koff R.S.
        • Laszlo A.
        • Wiholm B.E.
        • Shapiro S.
        Alcohol consumption and the risk of gastrointestinal bleeding.
        Am J Gastroenterol. 1995; 90: 1058-1064
        • Singh G.
        • Ramey D.R.
        • Morfeld D.
        • Shi H.
        • Hatoum H.T.
        • Fries J.F.
        Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis.
        Arch Intern Med. 1996; 156: 1530-1536
        • Singh G.
        Recent considerations in nonsteroidal anti-inflammatory drug gastropathy.
        Am J Med. 1998; 105: 31S-38S
        • Laine L.
        • Marin-Sorensen M.
        • Weinstein W.M.
        The histology of gastric erosions in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs).
        Gastroenterology. 1987; 94 (Abstr.): A247
        • Kim J.G.
        • Graham D.Y.
        Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy.
        Am J Gastroenterol. 1994; 89: 203-207
        • Graham D.Y.
        • Lidsky M.D.
        • Cox A.M.
        • et al.
        Long-term nonsteroidal anti-inflammatory drug use and Helicobacter infection.
        Gastroenterology. 1991; 100: 1653-1657
        • Laine L.
        • Marin-Sorensen M.
        • Weinstein W.M.
        Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development.
        Am J Gastroenterol. 1992; 87: 1398-1402
        • Taha A.S.
        • Sturrock R.D.
        • Russell R.I.
        Mucosal erosions in longterm non-steroidal anti-inflammatory drug users.
        Gut. 1995; 36: 334-336
        • Chan F.K.
        • Sung J.J.
        • Chung S.C.
        • et al.
        Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
        Lancet. 1997; 350: 975-979
        • Lai K.C.
        • Lam S.K.
        • Hui W.M.
        • et al.
        Can eradication of Helicobacter pylori prevent future development of peptic ulcers in patients receiving long-term continuous nonsteroidal anti-inflammatory drugs.
        Gastroenterology. 1998; 114 (Abstr.): A192
        • Hawkey C.J.
        • Tulassay Z.
        • Szczepanski L.
        • et al.
        Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs.
        Lancet. 1998; 352: 1016-1021